Haiden Huskamp, PhD
Haiden Huskamp, PhD, is a health economist and professor of health care policy. Dr. Huskamp has three primary areas of research: 1) mental health and substance use disorder policy; 2) prescription drug policy; and 3) the financing and utilization of end-of-life care services. She also serves as co-director of Harvard Medical School’s course on social and population sciences required of all first-year medical and dental students.
Dr. Huskamp recently served as principal investigator for an R01 funded by the National Institute of Mental Health (NIMH) focused on factors that influence physician adoption and use of antipsychotic medications, and currently serves as principal investigator for an R01 funded by the National Institute on Drug Abuse (NIDA) assessing the effects of new payment and delivery models on substance use disorder treatment. She recently served as principal investigator for an NIMH grant on the effect of mental health parity on individuals with severe mental illnesses and high mental health service costs. Dr. Huskamp has published numerous papers on the impact of managed care for mental health services on utilization patterns, costs, and quality of care. She recently served as a member of the Institute of Medicine Committee on Developing Evidence-Based Standards for Psychosocial Interventions for Mental Disorders.
Dr. Huskamp is an expert on the impact of pharmacy management tools used to control prescription drug costs on drug utilization, cost, and quality of care. She has written numerous papers on the Medicare Part D drug benefit and its implications for vulnerable populations, including individuals with a mental illness and nursing home residents. Through a Robert Wood Johnson Foundation Investigator Award in Health Policy Research, Dr. Huskamp examined the social costs and benefits of newer psychotropic drugs to assess their social value and identify ways that the value of psychotropic drug spending can be increased. She serves as principal investigator on an NIH-funded U01 grant examining characteristics of provider organizations that influence the diffusion of new technologies, including prescription drugs. She also served as a member of the Institute of Medicine Committee on Accelerating Rare Diseases Research and Orphan Products Development.
Dr. Huskamp’s research on end-of-life care includes a study of the changing characteristics of the hospice industry and the effects of industry changes on the provision of end-of-life care, a study of the timing of discussions about hospice care that occur between physicians and patients with metastatic lung cancer, and a study of patient-level variation in hospice costs. She served as a member of the Institute of Medicine Committee on Care for Children Who Die and Their Families, and she recently authored a paper on the financing of end-of-life care services published in the Institute of Medicine report “Dying in America.”
Health Affairs • Sep 2017
Health Affairs • Jul 2017
BMC Health Services Research • May 2017
Health Affairs • May 2017
JAMA Internal Medicine • Feb 2017